 Nes-Ziona, Israel, Feb. 16, 2021 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd., Nasdaq: ENLV, the Company, a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,927,343 covering AllocetraTM, the companys immunotherapy product candidate. The new patent is expected to provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohns disease, ulcerative colitis and graft versus host disease GvHD. 